Australia's INOVIQ surges as ovarian cancer test data impresses
02/06/2025 04:35
** Shares of INOVIQ IIQ.AX rise 36.4% to A$0.6, on track for their biggest intraday pct jump since early June 2024 ** Cancer diagnostics co hits highest level since August 22, 2024 ** New data shows Co's EXO-OC ovarian cancer test can accurately detects all early-stage I and II cancers with no missed diagnoses ** Says the test uses AI-enhanced algorithm to enable the early and accurate detection of ovarian cancer ** Stock up more than 16% this year, including the day's move (Reporting by John Biju in Bengaluru) ((John.Biju@thomsonreuters.com;))
Recent news on Inoviq
See all newsBrief: Inoviq Posts FY26 Net Loss After Tax A$7.5 Million
Brief: INOVIQ Requests Trading Halt
Brief: INOVIQ Says Peter Gunzburg Elected To Role Of Chairman
Brief: Inoviq Says Chairman David Williams To Step Down At Year-End
Australia's INOVIQ slips to 2-1/2-month low on $6.2 million discounted placement